Inhibitory effects of cryptoporus polysaccharide on airway constriction, eosinophil release,and chemotaxis in guinea pigs

作     者：Xiao-yan ZHAO, Qiang-min XIE2, Ji-qiang CHEN, Chuan-kui KE3 Zhejiang Respiratory Drugs Research Laboratory of State Drugs Administration of China, Medical School ofZhejiang University, Hangzhou 310031 3TSBIO Science& Technology Co,Ltd, Hangzhou 310006, China 

作者机构：浙江大学 国家食品药品监督管理局呼吸药物研究实验室 Hangzhou 310031 TSBIO Science & Technology CoLtd Hangzhou 310006 

出 版 物：《Acta Pharmacologica Sinica》 (中国药理学报(英文版))

年 卷 期：2004年第25卷第4期

页      面：105-109页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100706[医学-药理学] 100602[医学-中西医结合临床] 10[医学] 

基　　金：Project supported by the National Natural Science Foundation of China (No 39970857)and National New Drugs Research Foun-dation of China (No 96-901-05-269) 

主　　题：polysaccharide ovalbumin bronchoconstriction respiratory function tests eosinophil peroxidase platelet activating factor chemotaxis asthma guinea pig 

摘      要：AIM: To study effects of cryptoporus polysaccharide (CP) on antigen-induced bronchoconstriction, eosinophil peroxidase (EPO) release in vivo, and on platelet activating factor (PAF)-induced eosinophil chemotaxis in vitro in guinea pig. METHODS: The asthma model of guinea pig was formed with ovalbumin (OVA). The changes of lung resistance (RL) and dynamic lung compliance (Cdyn), EPO level in bronchoalveolar lavage fluids (BALF) and eosino- phil migration were determined. RESULTS: Pretreatment of CP at doses of 3, 9, and 27 mg/kg by intragastric gavage (ig), qd for 10 d, inhibited early asthma response in a dose-dependent manner. Inhibitory rates of mean increase value from 1 to 30 min of RL were 34.8 %, 74.4 % (P0.05), and 79.6 % (P0.05), respectively. Inhibi- tory rate of mean reduction value of Cdyn were 22.9 %, 40.5 % (P0.01), and 66.5 % (P0.01), respectively. Pretreatment of CP at doses of 3, 9, and 27 mg/kg also inhibited late asthma response, and the reduction of EPO level in BALF were 3.1 %, 16.9 % (P0.01), and 20.1 % (P0.01), respectively. The inhibitory rates of CP at concentrations of 0.13, 1.3, 13, 130 nmol/L to eosinophil migration induced by PAF were 6.8 %, 17.2 % (P0.05), 29.6 % (P0.01), and 35.9 % (P0.01). CONCLUSION: CP protects lung against increase of RL and reduction of Cdyn, decreases EPO level in the asthma model, and inhibits eosinophil chemotaxis induced by PAF. The results suggest that CP may be a novel antiinflammatory agent for the treatment of asthma and allergic diseases.